[go: up one dir, main page]

IN2015DN00524A - - Google Patents

Info

Publication number
IN2015DN00524A
IN2015DN00524A IN524DEN2015A IN2015DN00524A IN 2015DN00524 A IN2015DN00524 A IN 2015DN00524A IN 524DEN2015 A IN524DEN2015 A IN 524DEN2015A IN 2015DN00524 A IN2015DN00524 A IN 2015DN00524A
Authority
IN
India
Prior art keywords
arthritis
disease
rheumatoid arthritis
juvenile
allergic
Prior art date
Application number
Inventor
Joerg Martin Bentzien
Angela Kay Berry
Todd Bosanac
Michael Jason Burke
Darren Todd Disalvo
Joshua Courtney Horan
Shuang Liang
Can Mao
Wang Mao
Yue Shen
Fariba Soleymanzadeh
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00524(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2015DN00524A publication Critical patent/IN2015DN00524A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

THE PRESENT INVENTION ENCOMPASSES COMPOUNDS OF THE FORMULA (I) WHEREIN THE GROUPS A, CY, XI AND Y ARE DEFINED HEREIN, WHICH ARE SUITABLE FOR THE TREATMENT OF A DISEASE CHOSEN FROM RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHROMATOSIS, SCLERODERMA, ASTHMA, ALLERGIC RHINITIS, ALLERGIC ECZEMA, B CELL LYMPHOMA, MULTIPLE SCLEROSIS, JUVENILE RHEUMATOID ARTHRITIS, JUVENILE IDIOPATHIC ARTHRITIS, INFLAMMATORY BOWEL DISEASE, GRAFT VERSUS HOST DISEASE, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND UVEITIS.
IN524DEN2015 2012-08-10 2013-08-08 IN2015DN00524A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681684P 2012-08-10 2012-08-10
PCT/US2013/054096 WO2014025976A1 (en) 2012-08-10 2013-08-08 Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors

Publications (1)

Publication Number Publication Date
IN2015DN00524A true IN2015DN00524A (en) 2015-06-26

Family

ID=49029216

Family Applications (1)

Application Number Title Priority Date Filing Date
IN524DEN2015 IN2015DN00524A (en) 2012-08-10 2013-08-08

Country Status (25)

Country Link
US (5) US20140045813A1 (en)
EP (1) EP2882741B1 (en)
JP (1) JP6348492B2 (en)
KR (1) KR20150040292A (en)
CN (1) CN104603124B (en)
AP (1) AP2015008203A0 (en)
AU (1) AU2013299557B2 (en)
BR (1) BR112015002590A2 (en)
CA (1) CA2881519A1 (en)
CL (1) CL2015000256A1 (en)
EA (1) EA029210B1 (en)
EC (1) ECSP15008851A (en)
GE (1) GEP201706748B (en)
HK (1) HK1210161A1 (en)
IL (1) IL236495A0 (en)
IN (1) IN2015DN00524A (en)
MA (1) MA37830B1 (en)
MX (1) MX2015001802A (en)
NZ (1) NZ703607A (en)
PE (1) PE20150756A1 (en)
PH (1) PH12015500294A1 (en)
SA (1) SA515360007B1 (en)
SG (1) SG11201500499TA (en)
TN (1) TN2015000029A1 (en)
WO (1) WO2014025976A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CA2888960C (en) * 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
SI2970291T1 (en) * 2013-03-15 2022-07-29 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
KR102272792B1 (en) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
JP6486954B2 (en) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazole compounds as BTK inhibitors
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (en) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 Shandong tyrosine kinase inhibitor
CN105884747B (en) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 Preparation method for preparing Bruton's Tyrosine Kinase (BTK) kinase inhibitor
EA034561B1 (en) * 2015-12-16 2020-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Bipyrazolyl derivatives useful for treating autoimmune diseases
MD3390395T2 (en) * 2015-12-16 2021-02-28 Loxo Oncology Inc Ccompounds useful as kinase inhibitors
CN105646318A (en) * 2015-12-30 2016-06-08 武汉药明康德新药开发有限公司 Synthesis method of 2-tertbutyloxycarbonyl-5-azaspiro[3.3]heptane-6-carboxylic acid
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN107226805A (en) * 2016-03-24 2017-10-03 北京天诚医药科技有限公司 Aromatic amides analog derivative, its preparation method and its in application pharmaceutically
RU2749951C2 (en) * 2016-08-15 2021-06-21 Новартис Аг Regimen and methods for multiple sclerosis treatment using ofatumumab
CN107759602B (en) * 2016-08-17 2020-04-21 中国科学院上海药物研究所 Compounds containing conjugated allene structures, pharmaceutical compositions and uses thereof
JOP20190113A1 (en) * 2016-11-18 2019-05-15 Biocad Joint Stock Co Inhibitors of bruton’s tyrosine kinase
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019027860A1 (en) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh Intermediate compounds and methdods
TWI767148B (en) * 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020120673A1 (en) * 2018-12-13 2020-06-18 Intervet International B.V. Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide
KR102200032B1 (en) * 2019-03-13 2021-01-08 전남대학교산학협력단 Novel compound and composition for the prevention or treatment of respiratory diseases comprising the same
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020276334B2 (en) * 2019-05-10 2022-12-22 Henan Zhiwei Biomedicine Co., Ltd. Substituted 1-amino-1H-imidazole-5-carboxamide as Bruton's Tyrosine Kinase inhibitors
JP2023500906A (en) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Methods of treating cancers with acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022025732A2 (en) * 2020-06-19 2023-03-07 Anaxis Pharma Pty Ltd SULPHONAMIDE COMPOUNDS
CN114573586B (en) * 2020-11-28 2023-11-03 杭州和正医药有限公司 Polycyclic compound for inhibiting Bruton tyrosine kinase activity, pharmaceutical composition and application thereof
AU2022409472A1 (en) 2021-12-14 2024-06-27 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
AR130114A1 (en) * 2022-08-04 2024-11-06 Heptares Therapeutics Ltd MUSCARINIC RECEPTOR AGONISTS

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
AU2002331227B2 (en) * 2001-08-13 2008-01-24 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
JP2006515828A (en) * 2001-09-27 2006-06-08 スミスクライン・ビーチャム・コーポレイション Chemical compound
FR2881426B1 (en) * 2005-02-03 2007-03-30 Aventis Pharma Sa SUBSTITUTED PYROLLES AND IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME, PROCESS FOR FRABRICATION AND USE
JP2009536617A (en) * 2006-04-11 2009-10-15 バーテックス ファーマシューティカルズ インコーポレイテッド Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
PE20080839A1 (en) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
HUE025459T2 (en) * 2006-09-22 2016-05-30 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP2543375A1 (en) * 2007-03-28 2013-01-09 Pharmacyclics, Inc. Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase
CN102066366B (en) 2008-06-24 2014-04-16 霍夫曼-拉罗奇有限公司 Novel substituted pyridin-2-ones and pyridazin-3-ones
PL2310528T3 (en) 2008-07-29 2014-04-30 Univ Liege A genetic marker test for brachyspina and fertility in cattle
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
JP2012516329A (en) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryls and their use as PI3K inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2513066A1 (en) 2009-12-17 2012-10-24 Merck Patent GmbH Sphingosine kinase inhibitors
AU2011260961B9 (en) 2010-05-31 2015-02-26 Ono Pharmaceutical Co., Ltd. Purinone derivative
JP2013533318A (en) * 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryl and uses thereof
AR082590A1 (en) 2010-08-12 2012-12-19 Hoffmann La Roche INHIBITORS OF THE TIROSINA-QUINASA DE BRUTON
ES2590491T3 (en) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Bruton Tyrosine Kinase Inhibitors
EP2744804B1 (en) 2011-08-17 2017-05-17 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104080789B (en) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 As the ring molecule of bruton's tyrosine kinase inhibitor
CN104662018B (en) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 Substituted Heterobicyclic compounds, composition and its medical applications
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CA2881761A1 (en) 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
CA2888960C (en) 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
US20160207906A1 (en) 2013-09-03 2016-07-21 Carna Biosciences, Inc. Novel 2,6-diaminopyrimidine derivative
JP6486954B2 (en) 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazole compounds as BTK inhibitors
EA034561B1 (en) 2015-12-16 2020-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Bipyrazolyl derivatives useful for treating autoimmune diseases

Also Published As

Publication number Publication date
CN104603124A (en) 2015-05-06
MA20150290A1 (en) 2015-08-31
US20140045813A1 (en) 2014-02-13
BR112015002590A2 (en) 2019-08-06
MA37830B1 (en) 2018-09-28
WO2014025976A1 (en) 2014-02-13
EP2882741A1 (en) 2015-06-17
US20190112302A1 (en) 2019-04-18
AP2015008203A0 (en) 2015-01-31
JP6348492B2 (en) 2018-06-27
PH12015500294B1 (en) 2015-04-20
US20170320867A1 (en) 2017-11-09
US20180086748A1 (en) 2018-03-29
AU2013299557B2 (en) 2017-06-22
TN2015000029A1 (en) 2016-06-29
EP2882741B1 (en) 2018-10-24
US10875852B2 (en) 2020-12-29
PH12015500294A1 (en) 2015-04-20
CA2881519A1 (en) 2014-02-13
US20160031872A1 (en) 2016-02-04
CL2015000256A1 (en) 2015-07-03
AU2013299557A1 (en) 2015-01-29
SG11201500499TA (en) 2015-03-30
ECSP15008851A (en) 2015-12-31
EA029210B1 (en) 2018-02-28
IL236495A0 (en) 2015-02-26
HK1210161A1 (en) 2016-04-15
SA515360007B1 (en) 2016-09-04
GEP201706748B (en) 2017-10-10
PE20150756A1 (en) 2015-06-03
CN104603124B (en) 2018-04-17
JP2015524480A (en) 2015-08-24
US10138229B2 (en) 2018-11-27
NZ703607A (en) 2018-02-23
EA201500207A1 (en) 2015-08-31
KR20150040292A (en) 2015-04-14
MX2015001802A (en) 2015-05-07

Similar Documents

Publication Publication Date Title
IN2015DN00524A (en)
MX2015017973A (en) Primary carboxamides as btk inhibitors.
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
MX372962B (en) NEW BICYCLIC COMPOUNDS AS DUAL AUTOTAXIN (ATX)/CARBONIC ANHYDRASE (CA) INHIBITORS.
IN2014DN00176A (en)
EA201491622A1 (en) BISPECIFIC ANTIBODIES AGAINST BAFF AND IL-17
PH12015502814B1 (en) 4-membered ring carboxamides used as nematicides
PH12014502169A1 (en) N-cyclylamides as nematicides
MY182082A (en) Biheteroaryl compounds and uses thereof
MX2018003130A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2016011992A (en) Piperidine-dione derivatives.
MX2018001890A (en) Bicyclic compounds as atx inhibitors.
MD4521B1 (en) Antiviral compounds based on condensed imidazolyl-dihydroisochromeno-naphthoimidazols
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
PH12013500381B1 (en) N-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamides and use thereof as herbicides
MX2015012629A (en) Imidazo pyridine compounds.
PH12016501071A1 (en) Serine/threonine kinase inhibitors
PE20150182A1 (en) PHENOXYETHYL PIPERIDINE COMPOUNDS
MX2016001641A (en) Cyclobutyl carboxamides as nematicides.
MX2014013036A (en) 6-pyridone-2-carbamoyl-azoles and their use as herbicides.
MX2016014993A (en) Highly effective stabilizer.
NZ705902A (en) Isoxazolidine derivatives
MX2016000487A (en) Pyridine-2-carboxamides as nematocides.